Atara Biotherapeutics vs Dyadic International
ATRA and DYAI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and DYAI compare
Atara Biotherapeutics is the larger company, worth 5.5 times as much as Dyadic International ($64.2M against $11.7M).
Dyadic International grew revenue faster over the last twelve months (−7.6% versus −96.7% for Atara Biotherapeutics).
Dyadic International keeps more of each dollar of sales as profit, with a net margin of −227% compared with −269% at Atara Biotherapeutics.
Dyadic International scores higher on the StockData Score (7 against 3 for Atara Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | DYAI |
|---|---|---|
| Size and price | ||
| Market cap | $64.2M | $11.7M |
| Share price | $6.40 | $0.320 |
| Change, 1 year | −52.2% | −64.6% |
| Change, 5 years | −98.5% | −91.4% |
| Beta (5Y) | 2.01 | 1.44 |
| Employees | 14 | 5 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.4× | 3.8× (better) |
| Growth | ||
| Revenue growth (TTM) | −96.7% | −7.6% (better) |
| Revenue growth, 5Y average | – | 14.0% |
| Net income growth (TTM) | −388% | – |
| Profitability | ||
| Gross margin | – | 17.9% |
| Operating margin | −230% (better) | −237% |
| Net margin | −269% | −227% (better) |
| Return on equity | – | −47256% |
| Financial health | ||
| Interest coverage | −5.0× | – |
| Current ratio | 1.98 (better) | 1.69 |
| Altman Z-score | −136.13 | −18.95 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −14.4% | – |
| Shareholder yield | −14.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 12.7% |
| Held by insiders | 55.5% | 28.0% |
| Insider net buying, 12 months | $2.0M (better) | −$125K |
| Short interest, % of float | 6.6% | 0.32% |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- DYAI stock overview
- DYAI income statement
- DYAI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.